Whitehawk Therapeutics, Inc. WHWK
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Whitehawk Therapeutics, Inc. (WHWK) is a healthcare company listed in the US with a market value of about $181M. In fiscal year 2025 it had revenue of $7M and net income of -$21M, a net margin of -288.3%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -13% a year, a 5-year average ROIC of -76%.
About Whitehawk Therapeutics
Whitehawk Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $20M in 2018 to $7M in 2025, a decline of about 13.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 175% over three years (dilution for shareholders). It spends 1273% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7M | $26M | $24M | $15M | $14M | $14M | $0 | $20M | — | — |
| Net income | -$21M | -$64M | -$66M | -$61M | -$110M | -$3M | -$23M | -$10M | -$21M | -$17M |
| Free cash flow | -$98M | -$61M | -$64M | -$50M | -$22M | -$13M | -$24M | -$6M | -$19M | -$137814 |
| EPS (diluted) | $-0.33 | $-2.36 | $-2.44 | $-2.69 | $-12.41 | $-1.76 | $-9.56 | $-5.20 | $-17.27 | $-411.09 |
| Net margin | -288.3% | -245.1% | -270.0% | -397.7% | -786.4% | -24.8% | — | -51.6% | — | — |
| ROIC | -83.9% | -126.5% | -67.6% | -39.2% | -64.1% | — | — | -15.1% | -96.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Whitehawk Therapeutics pay a dividend?
Not currently.
Is Whitehawk Therapeutics a good stock to buy?
We do not give buy or sell advice. Whitehawk Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.